
Article 1 

1. The health claims listed in the Annex to this Regulation  may not be made on foods on the  Great Britain  market.
2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Article 2 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
This Regulation shall be binding in its entirety and directly applicable in all Member States.Done at Brussels, 3 May 2012.
For the Commission
The President
José Manuel BARROSO
ANNEX
Application – Relevant provisions of Regulation (EC) No 1924/2006 Nutrient, substance, food or food category Claim EFSA opinion reference
Article 14(1)(a) health claim referring to a reduction of a disease risk ProteQuine® ProteQuine® elevates/maintains the level of ScIgA on mucous membranes. Decreased or insufficient level of ScIgA is a risk factor in the development of common cold or influenza Q-2008-397
Article 14(1)(a) health claim referring to a reduction of a disease risk ProteQuine® in combination with bovine lactoferrin ProteQuine® in combination with bovine lactoferrin elevates/maintains the level of ScIgA on mucous membranes. Decreased or insufficient level of ScIgA is a risk factor in the development of common cold with sore throat and combination of ProteQuine® with bovine lactoferrin reduces the risk of the development of sore throat Q-2008-398
Article 14(1)(b) health claim referring to children's development and health Lactobacillus delbrueckii subsp. bulgaricus strain AY/CSL (LMG P-17224) and Streptococcus thermophilus strain 9Y/CSL (LMG P-17225) Maintaining the gut health by normalizing the intestinal flora Q-2008-273
Article 14(1)(b) health claim referring to children's development and health Beta palmitate Beta palmitate enrichment contributes to increase calcium absorption Q-2008-172